Advice

in the absence of a submission from the holder of the marketing authorisation:

zanubrutinib (Brukinsa®) is not recommended for use within NHSScotland.

Indication under review: in combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice229KB (PDF)

Download

Medicine details

Medicine name:
zanubrutinib (Brukinsa) SMC2671
SMC ID:
SMC2671
Indication:

In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.

Pharmaceutical company
BeiGene UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
13 May 2024